Background Periodontopathogens antibodies have been shown to be associated with primary myocardial events, but little is known regarding their impact on major adverse events after a prior acute myocardial infarction (AMI). The present prospective study evaluates the association between antibody levels of 4 periodontopathogens and the risk of all-cause death or non-fatal myocardial infarction (MI) at 1 year in 975 patients admitted for acute ST segment or non-ST segment elevation MI in French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI), a nationwide French survey.
Methods Multiserotype ELISAs were performed to assess levels of IgG and IgA against Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia and Tannerella forsythia.
Results Adjusted HRs indicate the lack of association between IgG-anti-Po. gingivalis levels (0.96 (0.78 to 1.18)), IgA-anti-Po. gingivalis levels (1.13 (0.90 to 1.42)) and the risk of all-cause death or non-fatal MI at 1 year. Additionally, no significant association was found between the occurence of an event at 1 year and immunoglobulins levels against the others periodontopathogens.
Conclusions The present data indicate that circulating levels of periodontopathogens antibodies are not associated with an increased risk of major adverse events in patients with a prior AMI. Studies dealing with bacterial and clinical data are needed to assess the role of oral health in comprehensive cardiac rehabilitation programmes.
- Cardiovascular disease
- Cohort studies
- DENTAL HEALTH
- Epidemiology of cardiovascular disease
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
AB and HR contributed equally.
Contributors AB, HR, ND, SK, TS, PB, SC and OM contributed to the planning of the work described in the manuscript. ND, TS, HR, EP, DT, GC and MZ contributed to the conduct of the study. AB, HR, SK, TS, PB, SC and OM contributed to the reporting of the study.
Funding FAST-MI is a registry of the French Society of Cardiology, supported by unrestricted grants from Pfizer and Servier and a research grant from the French Caisse Nationale d'Assurance Maladie. The multiserotype ELISA were also supported by a grant from Colgate–Palmolive Europe.
Competing interests None declared.
Ethics approval All procedures performed in this study involving human participants were in accordance with the ethical standards of the Committee for the Protection of Human Subjects in Biomedical Research of Saint Antoine University Hospital and the data file was declared to the ‘Commission Nationale Informatique et Liberté’ (CNIL) and with the 1964 Helsinki declaration and its later amendments.
Provenance and peer review Not commissioned; externally peer reviewed.